Shona Allen

WideTrial is a healthcare technology startup focused on bringing Expanded Access Programs (EAPs) to patients with life-threatening diseases and limited or no treatment options. I lead multi-site EAPs and partner with clinical, patient, and industry stakeholders to enable ethical, compliant access to investigational therapies in development. My work spans program management, patient engagement, regulatory alignment, and development of scalable patient-centric and site-centric processes.

o Lead the design, launch, and management of national, multi-site EAPs in neurology and oncology, including decentralized models with home health and central lab services

o Serve as a primary point of contact to sponsors, investigators, and external partners to drive alignment of cross-functional stakeholders and maintain clear communication, documentation, and project tracking

o Oversee program operations, including regulatory submissions, database configuration, vendor selection and oversight, supply coordination, and compliance documentation

o Develop patient-facing communication strategies and materials to support engagement, clarity of access pathways, and informed program design

o Build relationships with clinicians, KOLs, advocacy networks to support awareness, partnership, and meaningful feedback loops

o Provide training, guidance, and frontline support to clinical sites, ensuring readiness, compliance, and ethical handling of patient access requests

o Represent company initiatives at conferences and stakeholder meetings to strengthen visibility and collaboration

At Stanford's Neuromuscular Medicine group, I led a patient-centric, clinical trial design initiative focused on therapeutic development for Myotonic Dystrophy, a rare neuromuscular disease. My work integrated patient perspectives, outcome measure development, and biomarker strategy to inform trial design and development. I presented this work to clinical, industry, and academic audiences.

o Analyzed data from a sponsored phase 1 trial investigating a re-purposed small molecule for Type 1 Myotonic Dystrophy (DM1)

o Developed novel, patient-informed outcome measure tools, ensuring endpoints captured symptoms and impacts most meaningful to patients

o Applied advanced EEG data analytics (MNE-Python) to evaluate CNS treatment response, identifying potential biomarkers linked to DM1 CNS symptoms

o Synthesized insights from patient data, EEG biomarkers, and trial design to contribute to the development of a phase 1 trial strategy targeting CNS manifestations of DM1